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Abstract
Background: About 30% of patients with disseminated differentiated thyroid cancer (DTC) may experience a loss of iodine uptake. 
It is associated with higher aggressiveness of the tumour and a reduced 10-year survival rate. The diagnosis of non-radioiodine 
avid DTC metastases remains a diagnostic challenge. A helpful technique for this diagnosis is positron emission tomography 
with 2-[18F]fluoro-2-deoxy-D-glucose (PET/CT with [18F]FDG). On the other hand, there are still discussions about the clinical 
value of using exogenous thyroid-stimulating hormone (TSH) stimulation before PET/CT with [18F]FDG.
The aim of the study was the assessment of the usefulness of PET/CT with [18F]FDG under TSH suppression and stimulation 
of TSH performed in the detection of non-radioiodine avid DTC metastases, as well as determination of the thyroglobulin 
concentration under suppression and stimulation of TSH, which influences the result of PET/CT with [18F]FDG in patients with 
non-radioiodine avid DTC.
Material and methods: Retrospective analysis of 37 PET/CT with [18F]FDG performed in patients with DTC diagnosed and 
treated at the Department of Endocrinology and Isotope Therapy of the Military Institute of Medicine from January 2018 to July 
2020. Of these, PET/CT with [18F]FDG under exogenous rhTSH stimulation was performed in 22 patients and PET/CT with 
[18F]FDG under TSH suppression in 15 was performed. In all analyzed patients, the result of diagnostic whole-body scintigraphy 
(WBS) using 80 MBq 131I under rhTSH stimulation was negative, and the concentration of thyroglobulin after stimulation (sTg) 
was greater than 1.0 ng/mL.
Correspondence to: Maciej Kolodziej
Department of Endocrinology and Isotope Therapy, 
Military Institute of Medicine, Warsaw, Poland
e-mail: mkolodziej@wim.mil.pl
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles 
and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Nuclear Medicine Review 2021, Vol. 24, No. 2
www.journals.viamedica.pl/nuclear_medicine_review64
Original
Results: In the group of patients examined under TSH suppression, non-radioiodine avid in PET/CT with [18F]FDG were found 
in 6 out of 15 patients (40%) and in the group of patients examined under rhTSH stimulation in 10 out of 22 patients (45%). 
The differences between the groups were not statistically significant. The analysis of the receiver operating characteristic 
(ROC) curves allowed to determine the cut-off point for the positive result of PET/CT performed under TSH suppression with 
sTg concentration of 11.03 ng/mL. In the group of studies performed under rhTSH stimulation, the cut-off point for sTg was 
6.3 ng/mL. There was no statistically significant difference between the baseline thyroglobulin (natTg) and sTg levels and the 
positive PET/CT result. The administration of rhTSH before the PET/CT examination also had no statistically significant effect 
on the maximum standard uptake value (SUVmax) of the dominant lesion identified in the PET/CT.
Conclusions: 1) PET/CT with [18F]FDG is a useful tool for detection of non-radioiodine avid recurrence and/or metastases of 
DTC. 2) The concentration of natTg and sTg is highly correlated with a positive result of PET/CT with [18F]FDG. 3) The concen-
tration of natTg is comparable with sTg in predicting a positive result of PET/CT with [18F]FDG. 4) The cut-off point for a positive 
result of PET/CT for natTg was 1.36 ng/mL and for sTg was 7.05 ng/mL.
Key words: differentiated thyroid cancer; human recombinant TSH; thyroglobulin; whole-body scintigraphy; PET/CT; 
[18F]FDG; non-radioiodine avid thyroid cancer
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PET/CT examinations with [18F]FDG was performed between Janu-
ary 2018 and July 2020 in the group of patients of the Department 
of Endocrinology and Isotope Therapy of the Military Institute of 
Medicine in Warsaw (Tab. 1) after surgery and adjuvant treatment 
with 131I due to DTC. PET/CT was performed in patients who, 
during follow-up after the adjuvant therapy, showed an increased 
concentration of baseline thyroglobulin (natTg) and/or sTg and 
a negative result of the WBS performed after administration of 
80 MBq 131I. No recurrence and/or suspicious lymph nodes were 
found on ultrasound examination of the neck in any of the patients in 
the study group.
Of the analysed group, 40.5% (15/37) had PET/CT with [18F]FDG 
performed under TSH suppression, and 59.5% (22/37) under rhTSH 
stimulation (Thyrogen 0.9 mg administered twice intramuscularly 
with an interval of 24 hours).
PET/CT with [18F]FDG was performed at the Mazovian PET/CT 
Center Affidea in Warsaw. Post-stimulation PET/CT acquisition 
was performed 24 hours after the administration of the second 
dose of rhTSH.
PET/CT was performed 60 minutes after administration of 4 
MBq/kg of [18F]FDG on a hybrid Discovery 710 64-row scanner 
from General Electric Medical Systems.
The following parameters were used in the tomographic part 
of PET/CT: voltage: 140 kV, intensity (automatically adjusted to the 
patient’s weight): 40–100 mA, noise index: 22, the thickness of 
the tomographic layer in CT for absorption correction: 3.75 mm 
reconstructed to 1.25 mm, time lamp rotation: 0.8 s. The iterative 
reconstruction method was used in the PET study: the number 
of subsets: 18, the number of iterations: 3, the size of the matrix: 
256 × 256. The Time-of-Flight technique was used to improve the 
image contrast concerning noise.
Assessments of TSH (reference values: 0.27–4.2 µIU/mL) 
and Tg (reference values: 3.5–77 ng/mL) were performed at the 
Department of Laboratory Diagnostics of the Military Institute of 
Medicine using the electrochemiluminescence method (ECLIA) 
on the cobas e601 device from ROCHE Diagnostics, using 
ROCHE Diagnostics reagents. According to the DTC treatment 
Introduction
The concentration of thyroglobulin after stimulation of TSH (sTg) 
combined with whole-body diagnostic scintigraphy (WBS) using 
radioiodine (131I) is a recognized method that allows the follow-up 
of patients after ablative treatment of differentiated thyroid cancer 
(DTC) [1]. When the concentration of sTg is increased and there 
is no 131I uptake foci in WBS performed under endogenous or 
exogenous TSH stimulation, the non-radioiodine avid disease 
is suspected. It is an indication for positron emission tomogra-
phy (PET/CT) with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) 
[2]. Loss of iodine uptake may affect about 30% of patients with 
disseminated DTC [3, 4]. Such changes can be characterized by 
a poorer differentiation, usually higher aggressiveness and could 
show greater dynamics. The detection of non-radioiodine avid me-
tastases is associated with a reduction in the 10-year survival rate 
[3, 5, 6]. The sensitivity and specificity of PET/CT with [18F]FDG for 
this type of lesions is assessed as 68.4%–100% and 66.7%–98.5%, 
respectively [4, 7–12]. Studies show a strong correlation between 
the concentration of sTg and the presence of foci of increased 
metabolism of [18F]FDG in PET/CT [4, 13, 14].
Aim
The study aimed to compare the effectiveness of PET/CT with 
[18F]FDG performed under TSH suppression and recombinant 
human TSH (rhTSH) stimulation in detecting non-radioiodine avid 
foci of DTC in patients with a negative result of WBS with 131I and 
increased concentration sTg.
The aim of the study was also a determination of the thyroglob-
ulin concentration under suppression and stimulation of TSH, 
which influences the result of PET/CT with [18F]FDG in patients with 
non-radioiodine avid DTC.
Material and methods
The study was approved by the local Bioethics Committee at the 
Military Medical Chamber in Warsaw. A retrospective analysis of 37 
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guidelines, sTg concentrations above 1.0 ng/mL during follow-up 
were considered abnormal, which was one of the qualification 
criteria for PET/CT.
Ultrasound examinations were performed at the Department 
of Endocrinology and Isotope Therapy of the Military Institute of 
Medicine on the Acuson X150 device from Siemens with the use 
of a linear probe with a frequency of 8 MHz.
The WBSs were performed at the Department of Nuclear 
Medicine of the Military Institute of Medicine using NM/CT 870DR 
or Infinia VCHWK4 gamma-cameras from General Electric Medical 
System. The following parameters were used during the WBS: 
detector configuration: H-mode, energy window: 364 keV ± 10%, 
collimator: high-energy general-purpose (HEGP), body contour: 
on, scan mode: continuous, exposure time per pixel: 320 s, speed: 
7 cm/min, matrix: 256 × 1024, acquisition zoom: 1.
The obtained results were presented in the form of a mean 
with standard deviations or a median with extreme values, de-
pending on the fulfilment of the normal distribution conditions. 
Nominal variables are presented in the form of numbers with 
a frequency of occurrence. The compliance of the distribution 
of variables with the normal distribution was checked using the 
Shapiro-Wilk test. The correlation analysis was performed using the 
Pearson test for variables with a distribution close to the normal, 
otherwise, the Spearman test was used. Differences of nominal 
variables between groups were tested using the Chi-square test, 
and quantitative variables using the Student’s t-test for unrelated 
variables. To identify the cut-off points for the studied variables, ROC 
analysis was performed. The results of the performed tests were 
considered significant for the two-sided p < 0.05. All statistical 
analyses were performed using the Statistica v.12 package (Stat-
soft, Cracow, Poland).
Results
Among 37 PET/CT examinations with [18F]FDG, 15 were under 
TSH suppression (native-PET/CT — natPET/CT), and 22 were per-
formed under rhTSH stimulation (stimulated-PET/CT — sPET/CT). 
In the natPET/CT group, 6 (6/15 — 40%) positive results were 
obtained (natPET/CT+) (Fig. 1, 2). The remaining studies in 
this group (9/15 — 60%) were assessed as negative (natPET/CT–) 
and did not show any foci of increased metabolism of [18F]FDG 
related to the DTC. In the group of sPET/CT, 10 (10/22 — 45%) 
positive results (sPET/CT+) were obtained, finding foci of patho-
logical [18F]FDG uptake, which may correspond to recurrence or 
Table 1. Groups characteristic
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Figure 1A. PET/CT maximum intensity projection (MIP) performed 
under TSH suppression — accumulation of the [18F]FDG in the left 
cervical and right mediastinal lymph nodes
Figure 1B. PET/CT axial fusion projection performed under TSH 
suppression — accumulation of the [18F]FDG in the right mediastinal 
lymph node
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metastases of DTC (Fig. 3). The remaining studies in this group 
(12/22 — 55%) did not confirm the presence of foci of increased 
uptake of [18F]FDG (sPET/CT–). There were no statistically signifi-
cant differences between both groups (natPET/CT and sPET/CT) 
to obtain a positive result of PET/CT (PET/CT+).
The mean maximum standardized uptake value (SUVmax) in the 
dominant lesion shown in the natPET/CT+ group was 6.08 ± 2.87, 
and the tumour/background ratio for the reference point on me-
diastinal blood pool structures (MBPS) was 4.63 ± 2.35. In the 
sPET/CT+ group, these values  were respectively: 8.47 ± 5.38 
and 6.36 ± 4.18. However, these differences were not statistically 
significant (p = 0.18).
The median concentration of natTg and sTg measured 
during follow-up after 131I ablation treatment, which are the ba-
sis for qualification for PET/CT, in the natPET/CT group were, 
respectively: 1.07 ng/mL (0.04–190.3 ng/mL) and 6.87 ng/mL 
(1.45–882.0 ng/mL), and in the sPET/CT group: 0.54 ng/mL (0.04–
3069 ng/mL) and 4.87 ng/mL (0.56–4405 ng/mL).
A statistically significant positive correlation was found both 
between the concentration of natTg and sTg and the number of 
lesions in PET/CT (r = 0.71; p < 0.05 and r = 0.70; p < 0.05, 
respectively). The analysis of ROC curves for the whole group 
(both natPET/CT and sPET/CT) showed that for obtaining a pos-
itive result of PET/CT, the optimal cut-off point for natTg and sTg 
Figure 3A. PET/CT maximum intensity projection (MIP) performed 
under TSH stimulation — accumulation of the [18F]FDG in the right 
cervical lymph node
Figure 3B. PET/CT axial fusion projection performed under TSH 
stimulation — accumulation of the [18F]FDG in the right cervical lymph 
node
Figure 2A. PET/CT maximum intensity projection (MIP) performed 
under TSH suppression — multiple pulmonary metastasis
Figure 2B. PET/CT maximum intensity projection (MIP) performed 
under TSH suppression — multiple pulmonary metastasis
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concentrations is: 1.36 ng/mL (sensitivity 80.0%, specificity 85.0%, 
accuracy 82.3%) and 7.05 ng/mL (sensitivity 81.3%, specificity 
95.2%, accuracy 89.2%), respectively (Fig. 4, 5). However, the dif-
ferences in the area under the ROC curves (AUC) between natTg 
and sTg were not statistically significant (0.872 vs 0.879; p = 0.59).
The analysis of the ROC curves for the natPET/CT group 
showed that to obtain a positive result of PET/CT, the optimal cut-
off point for natTg and sTg concentrations is 2.7 ng/mL (sensitivity 
100.0%, specificity 87.5%, accuracy 92.3%) and 11.03 ng/mL (sen-
sitivity 100.0%, specificity 100.0%, accuracy 100.0%), respectively. 
For the sPET/CT group, the optimal cut-off point for natTg and sTg 
concentrations is 0.6ng/mL (sensitivity 80.0%, specificity 83.3%, ac-
curacy 81.8%) and 6.3 ng/mL (sensitivity 80.0%, specificity 100.0%, 
accuracy 90.9%), respectively. Nevertheless, the differences in AUC 
for natTg and sTg between the groups (natPET/CT vs sPET/CT) 
were not statistically significant (0.925 vs 0.817; p = 0.403 vs 1.000 
vs 0.833; p = 0.124).
Discussion
According to both the Polish recommendations and the Amer-
ican Thyroid Association (ATA) guidelines for the diagnosis and 
treatment of thyroid cancer, PET/CT with [18F]FDG is recommend-
ed in patients with increased thyroglobulin concentration and no 
pathological lesions in 131I WBS and/or ultrasound examination [1, 
15]. The authors of these recommendations do not specify the 
thyroglobulin cut-off point above which PET/CT should be con-
sidered. Nevertheless, in the same guidelines, sTg concentration 
above 10 ng/mL indicates an incomplete biochemical response to 
the ablation treatment [1, 15].
The present study found a positive correlation between both 
natTg and sTg concentration and the positive PET/CT result. 
Other authors confirmed the existence of such a correlation, but 
mainly concerning sTg. Trybek et al. [14] in 2014 showed that sTg 
has a strong and statistically significant accuracy in the diagnosis of 
recurrence and/or metastasis of differentiated thyroid cancer. Vural 
et al. [9] confirmed the relationship between the concentration of 
thyroglobulin under both suppression and stimulation of TSH, and 
the positive result of PET/CT. On the other hand, Shammas et al. 
[8] in a study from 2007 found that the sensitivity of PET/CT in-
creases with the concentration of natTg. Similar conclusions, but 
regarding sTg, were reached by Stangierski et al. [16] in 2016, 
confirming that the probability of obtaining a positive PET/CT 
result, i.e. showing foci of pathological metabolism [18F]FDG that 
may correspond to recurrence or metastasis of DTC, increas-
es with sTg concentration. In previous years, many authors have 
tried to establish a cut-off point for the sTg concentration above 
which it is reasonable to perform PET/CT with [18F]FDG. In a 2012 
South Korean study, Na et al. [12] estimated it at 20 ng/mL. In the 
same year, in a study conducted on 105 patients, Vural et al. [9] 
found that the cut-off point for natTg is 1.9 ng/mL, while for sTg it 
is 38.2 ng/mL with a sensitivity of 94% and a specificity of 100%. In 
the Polish study by Trybek et al. [14], the concentration of sTg with 
a sensitivity and specificity equal to 100% was 28.5 ng/mL, while 
in a Chinese study from 2017, Chai et al. [17] with a sensitivity of 
89.5% assessed was 49 ng/mL.
In the already cited Polish study by Stangierski et al. [16] 
the cut-off point for sTg was 32.9 ng/mL. This study found such 
correlation and established cut-off points for obtaining the pos-
itive result of PET/CT for both natTg and sTg at 1.36 ng/mL and 
Figure 4. The ROC curve for natTg in the prediction of positive result 
of PET/CT
Figure 5. The ROC curve for sTg in the prediction of positive result of 
PET/CT
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7.05 ng/mL, respectively. The threshold for natTg was lower, but 
similar to that obtained by Vural et al. [9], while the concentration 
of sTg determined by the authors was clearly lower than those 
mentioned in the above-cited studies, with a slightly lower, although 
still high, sensitivity. It was also lower than the values  mentioned in 
the Polish and American recommendations for the diagnosis and 
treatment of DTC.
At the same time, the authors did not find statistically signifi-
cant differences in the ROC curves for natTg with a cut-off point of 
1.36 ng/mL and for sTg with a cut-off point of 7.05 ng/mL. Thus, 
the values  of natTg and sTg in this study were comparable in pre-
dicting positive PET/CT in patients with non-radioiodine avid DTC. 
Therefore, it may be information that allows referring patients to 
PET/CT without prior assessment of sTg concentration. Due to 
the high costs of the rhTSH, basing the qualification of patients for 
PET/CT on the natTg concentrations performed in an outpatient 
setting should result in a lower burden for the health care system. 
Such an assumption was already made by the British group a few 
years ago, but then no useful cut-off point was found for natTg 
concentration [18].
The presented study did not find a statistically significant 
improvement in the detection of non-radioiodine avid recurrenc-
es and/or metastases of DTC using rhTSH stimulation before 
PET/CT, which is coherent with the observations of other authors [19, 
20]. However, there are also data in the literature suggesting 
that the use of rhTSH stimulation before PET/CT may increase 
its sensitivity from 28% to 50% [21]. Dionigi et al. [4] found that 
administration of rhTSH before PET/CT increases its sensitivity 
in detecting recurrence of differentiated thyroid cancer from 81% 
to 95%. Furthermore, the Chinese meta-analysis of Ma et al. [22] 
covering 7 prospective studies with a total of 168 patients showed 
that the use of exogenous or endogenous TSH stimulation before 
PET/CT statistically significantly increases the chance of obtaining 
a positive result (OR = 2.45; 95% CI 1.23–4.9) and statistically 
influences the number of foci of radiotracer accumulation visible 
in PET/CT (OR = 4.92; 95% CI 2.7–8.95).
The present analysis of ROC curves in subgroups, separately for 
positive PET/CT results in the non-stimulated group (natPET/CT+) 
and after rhTSH stimulation (sPET/CT+), showed that the optimal 
cut-off point for sTg concentration to obtain a positive result of 
PET/CT is 11.03 ng/mL in the natPET/CT group and 6.3 ng/mL in 
the sPET/CT group, respectively. However, this difference was not 
statistically significant, perhaps due to the too-small size of both 
groups. Still, this may be indirect proof of the validity of using rhTSH 
before PET/CT in patients with slightly elevated sTg concentration 
(above 6.3 ng/mL). For the sTg concentration almost twice as high 
(11.03 ng/mL), it may be sufficient to perform a PET/CT under TSH 
suppression. There are no studies in the available literature that 
would deal with this issue in this aspect in a larger group of patients. 
Saab et al. [23] in a study involving a group of 15 sPET/CT stated 
that the use of TSH stimulation (exogenous or endogenous) al-
lows for the identification of non-radioiodine avid metastases of DTC 
in PET/CT with relatively low sTg concertation, for which it was found 
to be 15 ng/mL. At the same time, these authors emphasize that 
PET/CT was useful regardless of the type of TSH stimulation. In 
the present study, all sPET/CT were performed with rhTSH, due 
to the proven equal, compared to endogenous, effectiveness of 
this type of TSH stimulation in the treatment and diagnosis of DTC, 
with a simultaneously reduced risk of side effects of the withdrawal 
of levothyroxine treatment [24–26].
The work of Vera et al. [19], on the other hand, indicated low 
effectiveness of the sPET/CT at a natTg concentration below 10 
ng/mL but did not take into the sTg concentration. The Brazilian 
study by Almeida et al. [27] compares the results of PET/CT before 
and after endogenous TSH stimulation (withdrawal of levothyroxine 
for 30 days). Due to the endogenous method of stimulation, the sTg 
concentration was measured only for the sPET/CT. In a German 
study, Petrich et al. [28] performed a head-to-head comparison 
of PET/CT before and after rhTSH stimulation in a group of 30 pa-
tients, but this work does not provide information on the analysis of 
ROC curves of sTg concentration for the natPET/CT and sPET/CT 
groups. On the other hand, these authors noticed that the use of 
rhTSH stimulation before PET/CT improved the tumour/background 
ratio of the identified lesions [28]. Other publications also indicate 
an improvement in the tumour/background ratio and an increase 
in SUVmax in PET/CT, which indicates better [18F]FDG uptake in 
metastatic lesions and leads to better PET/CT image quality [17, 
20, 27]. The authors obtained similar results in their work, but they 
were not statistically significant. This may be due to the insufficient 
size of the analysed group, but their observations are preliminary 
and will be continued in the future.
The advantage and innovative approach to the presented work 
is not only to show a positive, statistically significant correlation 
between natTg and sTg and positive result of PET/CT but also to 
show a comparable value of natTg and sTg in predicting a positive 
PET/CT result, as well as determining the cut-off point for natTg 
and sTg separately for natPET/CT+ and sPET/CT+.
The main limitation of the present work is the small size of the 
analysed group, but it is a preliminary study. The analyses will be 
continued on a wider group of patients in the future.
Conclusions
1. PET/CT with [18F]FDG is a useful tool for detection of non-radi-
oiodine avid recurrence and/or metastases of DTC.
2. The concentration of natTg and sTg is highly correlated with 
a positive result of PET/CT with [18F]FDG.
3. The concentration of natTg is comparable with sTg in predicting 
a positive result of PET/CT with [18F]FDG.
4. The cut-off point for a positive result of PET/CT for natTg 
was 1.36 ng/mL and for sTg was 7.05 ng/mL.
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